Alzchem Group AG and Crearene AG, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis. Dialysis is a treatment method which is applied for patients with a compromised kidney function, and which removes toxins, waste substances and salts from the blood.
Market Closed -
Other stock markets
|
After market 12:17:55 pm | |||
42 EUR | -3.23% | 41.85 | -0.36% |
Apr. 30 | Transcript : AlzChem Group AG, Q1 2024 Earnings Call, Apr 30, 2024 | |
Apr. 30 | AlzChem Group AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.54% | 476M | |
-1.76% | 74.28B | |
+0.53% | 46.91B | |
+2.63% | 32.93B | |
+9.24% | 17.78B | |
-6.46% | 12.09B | |
+12.74% | 11.88B | |
+0.03% | 10.66B | |
+2.36% | 9.55B | |
+4.35% | 8.28B |
- Stock Market
- Equities
- ACT Stock
- News AlzChem Group AG
- Alzchem and Crearene Develop Treatments for the Dialysis Market